Lytix Biopharma

[Hotdog]

Skal du delta i emisjonen?

• Ja definitivt
• Ja
• Kanskje
• Nei
• Aldri i verden

[toms]

Verrica resultater kommer akkurat litt for sent… det er mange som har sett emisjon komme hvert øyeblikk og fryktet en knusende rettet emisjon med full utvanning. Men nå er jeg hvertfall lettet, og regner med å tegne meg.

Emisjonen er ikke veldig stor ref at de brenner 20-25 mill I kvartalet. Så forventningene er nok gode resultater…

[TekBot]

Lytix Biopharma raising up to NOK 55 million with strong support from existing shareholders – several key milestones coming up with large commercial potential

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Any offering of the securities referred to in this announcement will be made by means of a national prospectus. This announcement is an advertisement and is not a prospectus. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned national prospectus, if a prospectus is published. Copies of any such prospectus will, following publication, be available from the company’s registered office and, subject to certain exceptions, on the website of the company.
…

Vis børsmeldingen

Oslo, April 9, 2024. Lytix Biopharma, a clinical-stage biotech company developing the future technology of cancer treatments, today announced the launch of a partially guaranteed share offering, raising a total of NOK 50 to 55 million. Lytix’s unique technology may overcome the major challenge of today’s cancer treatment, by generating broad tumor-specific immune responses in each patient.

“We are confident that Lytix will play a key role in tomorrow’s cancer treatment. Strong shareholder support enables us to take the company through important upcoming milestones, working towards realizing both the next steps of current clinical studies, such as the promising phase II study with our partner Verrica Pharmaceuticals, and the initiation of a new study in early-stage cancer patients at the Oslo University Hospital, Radiumhospitalet”, says Dr. Øystein Rekdal, CEO of Lytix Biopharma.

NOK 50 million of the amount is secured through pre-commitments by existing shareholders and subscription guarantees from a few selected new investors. The pre-commitments and subscription guarantees show the strong support of Lytix’s business model and technology.

Important read-out expected this summer
The funds will take the company into 2025, foreseen realizing several high potential value inflecting milestones. First and foremost, the upcoming read-out of Verrica’s Phase II trial for VP-315 (LTX-315) is expected this summer. The clinical study investigates the treatment of patients with skin cancer diseases (basal cell carcinoma).

Current surgical treatments for skin cancer can be invasive and painful, and may require the destruction of healthy tissue. LTX-315 represents a potential non-surgical alternative for patients suffering from skin cancer. Verrica has global rights for this market (basal cell carcinoma), a market which is alone expected to increase from USD 6.7 billion in 2021 to USD 11.4 billion by 2028.

“Our partnership with Verrica proves the potential application of our lead drug candidate in one of the biggest cancer indications globally, with a very large commercial potential. Furthermore, the licensing agreement enables us to realize values along the way, increasing our financial robustness. We are very much looking forward to the upcoming readout from Verrica”, continues Dr. Rekdal.

Lytix has to date received USD 3.5 million from Verrica. Under the licensing agreement, Lytix can receive up to USD 110 million in future development and sales milestones, with 10-15 percent royalties on future sales, based on reaching specific milestones.

Expanding into early-stage patients
Lytix has decided to expand its portfolio of clinical studies from late-stage cancer patients to patients with tumors able to be surgically removed, a less advanced disease, and a stronger immune system. Therefore, Lytix will co-finance a neoadjuvant study (ATLAS-IT-06) on melanoma patients with early-stage diseases, taking place at the Oslo University Hospital, Radiumhospitalet. The expected start-up is H1 2024.

“We’ve seen promising effects so far in our ongoing study (ATLAS-IT-05) showing stabilization of the disease in heavily treated patients. Introducing LTX-315 for early-stage patients can significantly increase the response rate, as well as having a greater commercial potential due to the market size”, adds Dr. Rekdal.

This patient population with a more robust immune system has a better chance of responding to Lytix’s immunotherapy, representing a commercial opportunity with a larger patient population.

Strong support from existing shareholders
The company has received binding pre-commitments from certain existing shareholders amounting to a total of NOK 40 million. Furthermore, a few new investors have guaranteed to subscribe for up to NOK 10 million. The application period for the Offer Shares commences, subject to publication of the prospectus, on 10 April 2024 and expires on or about 24 April 2024 at 16:00 hours (CEST), subject to any extensions.

Raising capital now is in line with the company’s previously communicated funding strategy and timeline. This is the first round of capital raise since the IPO in 2021, also supported by a strong cost discipline and adjustments over the past months.

Please see the prospectus for additional details on the transaction, including the risk factors associated with any investment in the company.

For more information, please contact:
Øystein Rekdal, CEO
+47 975 73 358
oystein.rekdal@lytixbiopharma.com

Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[TekBot]

Lytix Biopharma AS - Key information relating to the share offer

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 9 April 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS (“Lytix” or the “Company”) earlier today, regarding the contemplated launch of a partially guaranteed share offering (the “Offering”) of between 9,541,973 and 10,509,802 new shares (the “Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 5.24 per Offer Share pursuant to a prospectus dated 9 April 2024 and contemplated to be made public on or about 10 April 2024 (the “Prospectus”). The Offering will, if completed, raise gross proceeds of approximately between NOK 50 million and NOK 55 million. Key information relating to the Offering is set out below.
…

Vis børsmeldingen

The Offering does not constitute a rights issue as per Section 10-4 and Section 10-5 of the Norwegian Private Limited Liability Companies Act (the “Companies Act”). However, the Company’s existing shareholders as of 11 April 2024, as registered in the Norwegian Central Securities Depository (the “VPS”) two trading days thereafter (on 15 April 2024), who are not resident in a jurisdiction where such an offer would be illegal or would (excluding Norway) require the issuance of a prospectus, registration, or other similar action (the “Existing Shareholders”), will be allowed to participate in the Offering and will be given preference in the board’s allocation proposal of Offer Shares in accordance with their pro rata shareholding in the Company.

Date on which the terms and conditions of the Offering were announced: 9 April 2024

Last day granting a shareholder status as an Existing Shareholder with regards to the Offering: 11 April 2024

Ex-date: 12 April 2024

Record Date: 15 April 2024

Date of approval: 25 April 2024

Maximum number of new shares: 10,509,802

Subscription price: NOK 5.24 per Offer Share

Other information: It is important to clarify that Existing Shareholders are not to be considered as holders of subscription rights or similar rights to acquire Offer Shares. Existing Shareholders who want to apply for Offer Shares in Offering must complete the application form appended to the Prospectus and send it to the Company.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company’s continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[Dreamliner]

Det var en ordentlig måte å gjennomføre en emisjon på.

[Amaru]

Verrica har presentasjon i kveld kl. 20.15
https://verrica.com/press_release/verrica-pharmaceuticals-announces-presentation-at-the-23rd-annual-needham-virtual-healthcare-conference/

[drdr]

Vedr. LTX-315: resultat kommer innen juni!

[vegar_beider]

Juni var senere enn jeg trodde…

[TekBot]

Lytix Biopharma AS – Publication of Prospectus and commencement of Application Period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 10 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS (“Lytix” or the “Company”) yesterday, regarding the contemplated launch of a partially guaranteed share offering (the “Offering”) of between 9,541,973 and 10,509,802 new shares (the “Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 5.24 per Offer Share. The Offering will, if completed, raise gross proceeds of approximately between approximately NOK 50 million and NOK 55 million.
…

Vis børsmeldingen

Publication of Prospectus
The Company announces that the prospectus dated 9 April 2024 relating to the Company’s Offering (the “Prospectus”) has been registered by the Norwegian Register of Business Enterprises in accordance with section 7-8 of the Norwegian Securities Trading Act. The Prospectus is now available at the Company’s website https://www.lytixbiopharma.com/.

Neither the Financial Supervisory Authority of Norway nor any other public authority has carried out any form of review, control, or approval of the Prospectus. The Prospectus does not constitute an EEA-prospectus.

Commencement of Application Period
The application period for the Offering will commence tomorrow, on 10 April 2024, and expire on 24 April 2024 at 16:00 hours (CEST) (the “Application Period”), subject to any extensions. Further instructions regarding the application procedure are available in the Prospectus.

Advisors:
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.
Redeye AB is acting as financial advisor to the Company.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company’s continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO Lytix Biopharma AS
Phone: +47 952 60 512
E-mail: gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.
This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[TekBot]

Lytix Biopharma AS – Notice of extraordinary general meeting 25 April 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 10 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS (“Lytix” or the “Company”) yesterday and earlier today, regarding the launch of a partially guaranteed share offering (the “Offering”) based on a prospectus dated 9 April 2024. The Offering will, if completed, comprise between 9,541,973 and 10,509,802 new shares (the “Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 5.24 per Offer Share, raising gross proceeds of approximately between NOK 50 million and NOK 55 million.
…

Vis børsmeldingen

The application period for the Offer Shares commenced today, on 10 April 2024 and expires on or about 24 April 2024 at 16:00 hours (CEST) (the “Application Period”), subject to any extensions.

To resolve the necessary share capital increases to complete the Offering, the Company calls for an extraordinary general meeting (the “EGM”) on 25 April 2024 at 15:00 hours (CEST). The EGM will be held at the offices of Advokatfirmaet Thommessen AS located at Ruseløkkveien 38, 0251 Oslo, Norway

Please find attached the notice to the EGM. The notice is also available on the Company’s website, https://www.lytixbiopharma.com/.

The deadline for notice of attendance, proxies and advance voting for direct shareholders is 23 April 2024 at 16:00 hours (CEST). Notice of attendance, proxy forms and advance voting forms are attached to the notice to the EGM as Appendices 1 and 2, respectively. Owners of nominee registered shares must give such notice within the deadline (two business days prior to the general meeting) in order to participate in at the general meeting. The relevant form is asked to be sent to post@lytixbiopharma.com.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company’s continuing obligations as a company listed on Euronext Growth.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[Northien]

Er det noe som vet hvordan ATLAS-IT-06 skal finansieres? Skal doseringen/styrken av ltx-315 økes i denne studien?

[TekBot]

Lytix Biopharma AS: Tilbud om tegning av aksjer, publisering av prospekt og innkalling til ekstraordinær generalforsamling

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Innledning:
…

Vis børsmeldingen

Det vises til børsmeldinger fra Lytix Biopharma AS (“Selskapet” eller “Lytix”) publisert i går og tidligere i dag vedrørende et delvis garantert tilbud om tegning av mellom 9.541.973 og 10.509.802 nye aksjer (“Tilbudsaksjene”) i Selskapet (“Tilbudet”). Tilbudet vil være basert på et nasjonalt prospekt datert 9. april 2024 (“Prospektet”) som ble publisert tidligere i dag på Selskapets nettside (https://www.lytixbiopharma.com/). Gjennomføring av Tilbudet er avhengig av at generalforsamlingen vedtar å forhøye Selskapets aksjekapital. Selskapet har derfor kalt inn til ekstraordinær generalforsamling som avholdes 25. april 2024.

Børsmeldingene som ble publisert i går og tidligere i dag om Tilbudet var på engelsk. Selskapet publiserer i tillegg denne børsmeldingen på norsk som oppsummerer detaljene i Tilbudet og prosessen for deltakelse i Tilbudet. Denne børsmeldingen utgjør ikke en del av Tilbudet. Personer som er interessert i å delta i Tilbudet oppfordres til å lese Prospektet i sin helhet.

Tilbudet:
Tilbudet omfatter mellom 9.541.973 og 10.509.802 Tilbudsaksjer pålydende NOK 0,10, til en tegningskurs på NOK 5,24 per aksje. Tilbudet vil, hvis det gjennomføres, tilføre Selskapet mellom NOK 50 millioner og NOK 55 millioner før kostnader trekkes fra. Kostnadene er per nå beregnet til ca. NOK 4,2 millioner, der NOK 2,5 millioner er provisjon for forhåndstegninger og garantitegninger. Resterende NOK 1,7 million er honorar til juridiske og finansielle rådgivere.

Selv om Selskapet har mottatt bindende forhåndstegninger og garantier på til sammen NOK 50 millioner, så vil alle eksisterende Aksjonærer (som definert nedenfor) ha lik rett til å delta i Tilbudet og ha lik allokeringsprioritet. Dette innebærer at dersom det er god interesse for Tilbudet blant Aksjonærene, vil Aksjonærene bli allokert hele Tilbudet (MNOK 55). Fordeling av Tilbudsaksjer blant Aksjonærene vil utelukkende gjøres pro rata basert på eierandel.

Slik Tilbudet er utformet, er det ikke en fortrinnsrettsemisjon etter aksjeloven. Reelt gir imidlertid Tilbudet en full fortrinnsrett til Aksjonærene da disse har prioritet i allokeringen.

Personer som ønsker å tegne Tilbudsaksjer oppfordres til å lese Prospektet i sin helhet. Tegning av Tilbudsaksjer gjøres ved å fylle ut bestillingsblanketten (Application Form) som finnes i Prospektet og sende den inn til Selskapet.

Tilbudet er rettet mot:
(i) Selskapets aksjonærer per 11. april 2024, som registrert i Verdipapirsentralen (“VPS”) to handelsdager etterpå (15. april 2024), og som ikke er bosatt i en jurisdiksjon (utenom Norge) der et slikt tilbud ville være ulovlig eller ville kreve utstedelse av et prospekt, registrering eller andre lignende tiltak (“Aksjonærene”);

(ii) visse nye investorer som har garantert å tegne aksjer i Tilbudet på visse vilkår (“Investorgarantistene”); og

(iii) utvalgte potensielle investorer etter styrets skjønn (“Potensielle Investorer”).

Aksjer i Selskapet ervervet etter 11. april 2024 vil ikke gi rett til å delta i Tilbudet. Dette innebærer at 11. april 2024 er siste handelsdag hvor aksjene i Selskapets omsettes med en rettighet til å delta i – og være garantert allokering for en pro-rata andel av – Tilbudet.

Alle Aksjonærene vil ha allokeringsprioritet. Det betyr at Aksjonærer som bestiller Tilbudsaksjer, minst vil motta Tilbudsaksjer tilsvarende Aksjonærens pro-rata eierandel (basert på antall aksjer eid per 11. april 2024) i Selskapet (gitt at Aksjonæren har lagt inn en tilstrekkelig stor bestilling). De Potensielle Investorene vil kun bli tildelt Tilbudsaksjer dersom Tilbudet ikke blir fulltegnet av Aksjonærene, og Investorgarantistene vil kun bli tildelt aksjer i den grad Aksjonærene og de Potensielle Investorene ikke tegner Tilbudsaksjer for minimum NOK 50 millioner (“Minimumstegningen”).

Tilbudet gjennomføres ikke som en formell fortrinnsrettsemisjon i tråd med aksjeloven § 10-4, jf. § 10-5. Ingen tegningsretter utstedes derfor i forbindelse med Tilbudet. Aksjonærer som ønsker å søke om Tilbudsaksjer må bruke bestillingsskjemaet som er vedlagt Prospektet.

Selskapet har mottatt bindende forhåndstegninger fra visse Aksjonærer (“Aksjonærgarantistene”) om å tegne Tilbudsaksjer for totalt NOK 40 millioner. Som kompensasjon for denne forpliktelsen skal hver Aksjonærgarantist motta en provisjon på 5 % av deres respektive garantiforpliktelse. Provisjonen gjøres opp ved utstedelse av nye aksjer i Selskapet.

Videre har Investorgarantistene garantert å tegne Tilbudsaksjer for totalt opptil NOK 10 millioner, i den grad det er nødvendig for at Selskapet skal oppnå Minimumstegningen. Som kompensasjon for denne forpliktelsen skal hver Investorgarantist motta en provisjon på 5 % av deres respektive garantiforpliktelse. Provisjonen gjøres opp ved utstedelse av nye aksjer i Selskapet, eller, etter Selskapets valg, i kontanter.

Selskapet har kalt inn til ekstraordinær generalforsamling 25. april 2024, der generalforsamlingen forventes å vedta å øke aksjekapitalen for å gjennomføre Tilbudet. Beskjed om tildeling av Tilbudsaksjer og betalingsinstruksjoner forventes å bli distribuert rundt 25. april 2024, forutsatt at betingelsene for gjennomføring av Tilbudet er oppfylt. Betalingsfrist er forventet å være 30. april 2024.

Tilbudsaksjene vil, når de er utstedt, bli registrert i VPS i elektronisk form og forventes å bli levert i VPS i løpet av første halvdel av mai 2024. Det forventes at Tilbudsaksjene vil bli opptatt til handel på Euronext Growth i forbindelse med levering i VPS. Tilbudsaksjene vil ha like rettigheter og rangere pari passu med Selskapets eksisterende aksjer.

Gjennomføringen av Tilbudet er betinget av (i) at alle nødvendige selskapsbeslutninger blir gyldig truffet av Selskapet, inkludert, men ikke begrenset til, at generalforsamlingen i Selskapet vedtar å utstede Tilbudsaksjene, og (ii) at tegnerne innbetaler tegningsbeløpet.

Selskapet forbeholder seg retten til når som helst og av hvilken som helst grunn å avlyse og/eller endre vilkårene for Tilbudet. Selskapet vil ikke være ansvarlig for eventuelle tap som følge av at Tilbudet blir avlyst, uavhengig av årsaken til en slik avlysning.

Prospekt:
Selskapet har i forbindelse med Tilbudet utarbeidet Prospektet. Prospektet er et nasjonalt prospekt registrert hos Foretaksregisteret i tråd med § 7-8 i verdipapirhandelloven. Verken Finanstilsynet eller noen annen offentlig myndighet har gjennomført noen form for gjennomgang, kontroll eller godkjenning av Prospektet. Prospektet utgjør ikke et EØS-prospekt. Prospektet er tilgjengelig på Selskapets hjemmeside.

Personer som ønsker å tegne Tilbudsaksjer oppfordres til å lese Prospektet i sin helhet.

Ekstraordinær generalforsamling 25. april 2024:
Selskapet har tidligere i dag kalt inn til ekstraordinær generalforsamling 25. april 2024 kl. 15:00 for vedta kapitalforhøyelsene som er nødvendig for å gjennomføre Tilbudet. Generalforsamlingen vil bli avholdt i lokalene i Advokatfirmaet Thommessen AS i Ruseløkkveien 38, 0251 Oslo, Norge. Innkallingen er publisert på Selskapets nettside (https://www.lytixbiopharma.com/)

Fristen for påmelding, fullmakter og forhåndsstemming for direkte aksjonærer er 23. april 2024 kl. 16:00. Påmeldingsskjema, fullmaktsskjema og skjema for forhåndsstemming er vedlagt innkallingen til generalforsamlingen. Eiere av forvalterregisterte aksjer må gi slik melding innen fristen (to virkedager før generalforsamlingen) for å kunne delta på generalforsamlingen. Det relevante skjemaet bes sendt til post@lytixbiopharma.com.

Viktig informasjon om Tilbudet:
Datoen da vilkårene for Tilbudet ble kunngjort: 9. april 2024

Siste dag med handel for å oppnå status som Aksjonær med hensyn til Tilbudet: 11. april 2024

Første dag med handel uten status som Aksjonær med hensyn til Tilbudet (ex-dato): 12. april 2024

Registreringsdato: 15. april 2024

Dato for godkjenning av Tilbudet: 25. april 2024

Maksimalt antall nye aksjer: 10.509.802

Tegningspris: NOK 5,24 per Tilbudsaksje

Annen informasjon: Det er viktig å klargjøre at Aksjonærer ikke skal anses som innehavere av tegningsretter eller lignende rettigheter til å erverve Tilbudsaksjer. Aksjonærer som ønsker å tegne Tilbudsaksjer må fylle ut bestillingsskjemaet som er vedlagt Prospektet og sende det til Selskapet.

Rådgivere:
Advokatfirmaet Thommessen AS er juridisk rådgiver for Selskapet.
Redeye AB er finansiell rådgiver for Selskapet.

Bakgrunn for offentliggjøring:
Denne informasjonen er underlagt en opplysningsplikt i henhold til Selskapets løpende forpliktelser som et selskap notert på Euronext Growth.

For ytterligere opplysninger, kontakt:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[Do2Do]

“Slik Tilbudet er utformet, er det ikke en fortrinnsrettsemisjon etter aksjeloven. Reelt gir imidlertid Tilbudet en full fortrinnsrett til Aksjonærene da disse har prioritet i allokeringen.”

[Hotdog]

Leser også det som at det er en prorata tildeling. Fin og ryddig emisjon der evt utvanning kun blir ca 25%.

[TekBot]

Lytix Biopharma AS – Ex Date

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 12 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS (“Lytix” or the “Company”) on 9 April 2024 and 10 April 2024, regarding the launch of a partially guaranteed share offering (the “Offering”) based on a prospectus dated 9 April 2024. The Offering will, if completed, comprise between 9,541,973 and 10,509,802 new shares (the “Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 5.24 per Offer Share, raising gross proceeds of approximately between NOK 50 million and NOK 55 million. The application period for the Offer Shares commenced on 10 April 2024 and expires on or about 24 April 2024 at 16:00 hours (CEST), subject to any extensions.
…

Vis børsmeldingen

The shares in Lytix will today, 12 April 2024, be traded ex (i.e. without) granting a shareholder status as an Existing Shareholder (as defined below) in the Offering.

The Offering does not constitute a rights issue as per Section 10-4 and Section 10-5 of the Norwegian Private Limited Liability Companies Act. However, the Company’s existing shareholders as of 11 April 2024, as registered in the Norwegian Central Securities Depository (the “VPS”) two trading days later, who are not resident in a jurisdiction where such an offer would be illegal or would (excluding Norway) require the issuance of a prospectus, registration, or other similar action (the “Existing Shareholders”), will be given preference in the board’s allocation proposal of Offer Shares in accordance with their pro rata shareholding in the Company.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company’s continuing obligations as a company listed on Euronext Growth.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[TekBot]

Lytix Biopharma AS - Last day of the Application Period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 24 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS (“Lytix” or the “Company”) on 9 April 2024 and 10 April 2024, regarding the launch of a partially guaranteed share offering (the “Offering”) based on a prospectus dated 9 April 2024 (the “Prospectus”). The Offering will, if completed, comprise between 9,541,973 and 10,509,802 new shares (the “Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 5.24 per Offer Share, raising gross proceeds of approximately NOK 50 million to NOK 55 million.
…

Vis børsmeldingen

The application period for the Offer Shares commenced on 10 April 2024 and will expire today, 24 April 2024, at 16:00 hours (CEST) (the “Application Period”). Correctly completed application forms must be received by the Company by the end of the Application Period. Further instructions regarding the application procedure are available in the Prospectus. The Prospectus is accessible on the Company’s website at https://www.lytixbiopharma.com.

Completion of the Offering is subject to approval from the Company’s general meeting.

Advisors:
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.
Redeye AB is acting as financial advisor to the Company.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company’s continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[TekBot]

LYTIX BIOPHARMA AS – PRELIMINARY RESULTS IN THE SHARE OFFERING

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 24 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS (“Lytix” or the “Company”) on 9 and 10 April 2024, regarding the launch of a partially guaranteed share offering (the “Offering”) based on a prospectus dated 9 April 2024 (the “Prospectus”). The application period for the Offering expired today, on 24 April 2024, at 16:00 hours (CEST). At the expiration of the application period, the Company had received valid applications to subscribe for the Offer Shares, resulting in the total size of the Offering amounting to NOK 50 million (including Offer Shares subscribed for based on pre-commitments and guarantees).
…

Vis børsmeldingen

The Offering attracted strong interest from both existing and new high-quality investors.

“We are very pleased by the strong support from existing shareholders as well as interest from new investors. This is yet another validation of our technology and showcases the great business potential of Lytix. Our unique technology may overcome cancer heterogeneity - the major challenge of today’s cancer treatment - by generating broad tumor-specific immune responses in cancer patients,” says Dr. Øystein Rekdal, CEO of Lytix.

Lytix expects multiple key value-inflecting milestones in the coming period, related to the Company’s two ongoing phase II studies in cancer patients with different types of skin cancer diseases. Furthermore, the Company will commence another phase II study in Norway in early-stage melanoma patients, at the Oslo University Hospital, Radium Hospitalet.

“We are becoming a mature clinical company – with several phase II studies ongoing investigating major cancer indications worldwide. The next months will be marked by several exciting milestones, such as the results this summer from the promising phase II study with our licensing partner Verrica Pharmaceuticals. This study is investigating the treatment of patients with skin cancer diseases (basal cell carcinoma) and has great market potential, including milestone payments to Lytix.” he says.

The board of directors of the Company has called for an extraordinary general meeting to take place on 25 April 2024 (the “EGM”) to resolve the issuance of the Offer Shares. Based on the received applications, the board proposes that the Company issues Offer Shares to raise gross proceeds of NOK 50 million in accordance with the allocation criteria set out in the Prospectus. Completion of the Offering is subject to approval from the EGM.

All Shareholders (as defined the Prospectus) who have applied for Offer Shares will receive a full allocation in the Offering. Notifications of allocated Offer Shares and the corresponding subscription amount to be paid by each subscriber are expected to be distributed on or about 25 April 2024, subject to the EGM’s approval of the Offering. Payment for the allocated Offer Shares is expected to fall due on 30 April 2024.

The Offer Shares may not be transferred or traded until they have been fully paid for, and the share capital increase related to the Offering has been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). Registration of the share capital increase is anticipated to occur during the first half of May 2024. Subsequently, the Offer Shares are expected to be registered in the Norwegian Central Securities Depository (the “VPS”) in book-entry form and delivered to the applicants’ VPS accounts approximately on the same day. It is also anticipated that the Offer Shares will be admitted to trading on Euronext Growth concurrently with their delivery to the applicants’ VPS accounts.

Advisors:
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.
Redeye AB is acting as financial advisor to the Company.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company’s continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Important notices:
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at (i) qualified investors in that Member State within the meaning of the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons , subject to obtaining the prior consent of the Company for any such offer, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and (6) of the Prospectus Regulation, that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as Relevant Persons). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons.

Persons distributing this communication must satisfy themselves that it is lawful to do so.

The information contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this announcement and does not accept any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. The Company accepts no liability arising from the use of this announcement.

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[Hotdog]

Har dere troen på kurs oppgang fremover, nå når emisjon/penger er på plass:

• Ja rett til værs
• Tja
• Vet ikke
• Nei
• Raser nedover
• Trenger mere penger snart

[TekBot]

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity.

Oslo, 25 April 2024. Lytix Biopharma announces that the Norwegian Medical Products Agency has approved the clinical trial application for a Phase II Neoadjuvant study in early-stage melanoma, a severe form of skin cancer. In this study, Lytix`s lead candidate LTX-315 will be given in combination with another type of immunotherapy before surgery. The study is called NeoLIPA and will be led by Dr. Henrik Jespersen, Head of Melanoma Oncology at Radiumhospitalet (Oslo University Hospital).

“We are very excited to start the NeoLIPA study and investigate the clinical effect of LTX-315 in combination with the anti-PD-1 immune checkpoint inhibitor pembrolizumab in early-stage melanoma patients. By directly killing cancer cells in the injected tumor, LTX-315 can shrink the tumor locally before surgery and at the same time induce tumor-specific immune responses in the patient that potentially can reduce the risk of relapse of the disease after surgery” says Dr. Henrik Jespersen.
…

Vis børsmeldingen

Melanoma is the fastest growing cancer in large parts of Europe and North America. The increase is often attributed to increased exposure to ultraviolet radiation because of changed sun habits.
The Oslo University Hospital plan to start recruiting patients before the summer. The neoadjuvant study will be a Phase II, open-label study recruiting 27 patients with clinically detectable and resectable stage III-IV melanoma. Following the start-up in Oslo, Lytix Biopharma will have a portfolio of three ongoing phase II studies.

Expanding from late-stage patients
Lytix has previously announced positive interim results from the ongoing Phase II study in late-stage and heavily pre-treated patients (ATLAS-IT-05). Introducing LTX-315 to early-stage patients with less advanced disease and stronger immune system could represent a significant commercial opportunity, as this patient population is much larger and neoadjuvant therapy is becoming standard of care.

“The approval to start testing LTX-315 in earlier-stage patients in a neoadjuvant setting is a significant milestone for Lytix Biopharma. This patient population is expected to respond better to LTX-315 treatment since these patients generally will have a more robust and responsive immune system. We are very much looking forward to collaborating with Dr. Jespersen who is a very experienced melanoma expert,” says Øystein Rekdal, CEO of Lytix Biopharma.

The study will be an investigator-led study. Hence, specific to Lytix Biopharma, the cost exposure is mostly limited to drug supply.

Multiple studies
Including the NeoLIPA study in Oslo, Lytix`s lead candidate LTX-315 is tested in currently tested in three different phase II studies; One with its licensing partner Verrica Pharmaceuticals in the US in patients with the most common type of skin cancer (basal cell carcinoma) and one in late-stage melanoma patients.

“We are now becoming a more mature clinical company – with several phase II studies ongoing investigating major cancer indications worldwide. The next months will be marked by several exciting milestones, such as the results from the promising phase II study with Verrica and the start-up in early-stage patients in Oslo.” Rekdal says.

For more information, please contact:
Øystein Rekdal, CEO
Oystein.Rekdal@lytixbiopharma.com
+47 975 73 358

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[TekBot]

Lytix Biopharma annonserer godkjennelse av fase II-studie i pasienter med tidligfase føflekkreft (melanom) - en betydelig kommersiell mulighet

Oslo, 25. april 2024. Direktoratet for medisinske produkter har godkjent søknaden for en fase II neoadjuvant studie i tidligfase føflekkreft (melanom), som er en alvorlig form for hudkreft. I studien vil Lytix’ ledende legemiddel kandidat, LTX-315, bli gitt i kombinasjon med en annen type immunterapi før kirurgi. Studien har fått navnet NeoLIPA og vil ledes av Dr. Henrik Jespersen, leder for melanom-onkologi ved Radiumhospitalet (Oslo universitetssykehus).

• Vi er veldig spente på å starte NeoLIPA-studien og undersøke den kliniske effekten av LTX-315 i kombinasjon med anti-PD-1 sjekkpunkthemmeren pembrolizumab hos pasienter med tidig stadium melanom. Ved å direkte drepe kreftceller i den injiserte svulsten, kan LTX-315 redusere svulsten lokalt før kirurgi og samtidig aktivere kreft-spesifikke immunresponser hos pasienten som potensielt kan redusere risikoen for tilbakefall av sykdommen etter kirurgi, sier Dr. Henrik Jespersen.
  …

Vis børsmeldingen

Melanom er den raskest økende kreftsykdommen i Norge og store deler av Europa og Nord-Amerika. Økningen tilskrives ofte økt eksponering for ultrafiolett stråling som følge av endrede solvaner.
Oslo universitetssykehus planlegger å starte rekruttering av pasienter før sommeren. Denne neoadjuvant studien vil være en fase II-studie som inkluderer 27 pasienter med klinisk påvisbar og operabel stadium III-IV melanom. Etter oppstarten av denne studien på Radiumhospitalet (OUS) i Oslo, vil Lytix Biopharma ha en portefølje med tre pågående fase II-studier.

Utvidelse til ny pasientgruppe
Lytix har tidligere annonsert positive, foreløpige resultater fra den pågående fase II-studien hos senfase melanom pasienter som har gjennomgått flere tidligere behandlinger (ATLAS-IT-05). Introduksjon av LTX-315 til pasienter med tidligere stadier av sykdommen, og med et sterkere immunforsvar, kan representere en betydelig kommersiell mulighet. Denne pasientgruppen er langt større, samt at neoadjuvant immunterapi er en stadig mer vanlig form for behandling.

“Godkjennelsen for å begynne testing med LTX-315 hos pasienter i tidligere stadier av sykdommen i en neoadjuvant setting er en viktig milepæl for Lytix Biopharma. Ettersom denne pasientgruppen generelt vil ha et bedre og sterkere immunforsvar forventes disse pasientene å respondere bedre på behandlingen med LTX-315. Vi ser frem til å samarbeide med Dr. Jespersen, en svært erfaren hudmelanom-ekspert,” sier Øystein Rekdal, administrerende direktør i Lytix Biopharma.

Studien vil være en utprøver-initiert studie. Kostnadsbasen for Lytix Biopharma vil dermed hovedsakelig være begrenset til leveranse av legemiddel.

Flere studier
Med oppstart av NeoLIPA-studien i Oslo, blir Lytix’ ledende legemiddel kandidat, LTX-315, testet i tre forskjellige fase II-studier; Én studie ledet av selskapets lisenspartner Verrica Pharmaceuticals i USA på pasienter med den vanligste typen hudkreft (basalcellekarsinom) og én studie på pasienter med senfase melanom.

“Vi er på vei til å bli et mer modent, klinisk immunonkologis selskap - med flere fase II-studier pågående på store kreftindikasjoner. I løpet av de neste månedene forventes flere spennende milepæler, blant annet resultater fra den lovende fase II-studien med Verrica og oppstarten av NeoLIPA studien i pasienter med tidligere stadier av melanom i Oslo,” sier Rekdal.

For mer informasjon:
Øystein Rekdal, CEO
Oystein.Rekdal@lytixbiopharma.com
+47 975 73 358

Kilde